1. Home
  2. DMB vs NKTR Comparison

DMB vs NKTR Comparison

Compare DMB & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMB
  • NKTR
  • Stock Information
  • Founded
  • DMB 2013
  • NKTR 1990
  • Country
  • DMB United States
  • NKTR United States
  • Employees
  • DMB N/A
  • NKTR N/A
  • Industry
  • DMB Trusts Except Educational Religious and Charitable
  • NKTR Biotechnology: Pharmaceutical Preparations
  • Sector
  • DMB Finance
  • NKTR Health Care
  • Exchange
  • DMB Nasdaq
  • NKTR Nasdaq
  • Market Cap
  • DMB 182.2M
  • NKTR 160.4M
  • IPO Year
  • DMB N/A
  • NKTR 1994
  • Fundamental
  • Price
  • DMB $9.89
  • NKTR $0.66
  • Analyst Decision
  • DMB
  • NKTR Strong Buy
  • Analyst Count
  • DMB 0
  • NKTR 6
  • Target Price
  • DMB N/A
  • NKTR $4.92
  • AVG Volume (30 Days)
  • DMB 76.6K
  • NKTR 2.8M
  • Earning Date
  • DMB 01-01-0001
  • NKTR 05-08-2025
  • Dividend Yield
  • DMB 4.17%
  • NKTR N/A
  • EPS Growth
  • DMB N/A
  • NKTR N/A
  • EPS
  • DMB N/A
  • NKTR N/A
  • Revenue
  • DMB N/A
  • NKTR $98,427,000.00
  • Revenue This Year
  • DMB N/A
  • NKTR N/A
  • Revenue Next Year
  • DMB N/A
  • NKTR N/A
  • P/E Ratio
  • DMB N/A
  • NKTR N/A
  • Revenue Growth
  • DMB N/A
  • NKTR 9.21
  • 52 Week Low
  • DMB $8.94
  • NKTR $0.43
  • 52 Week High
  • DMB $11.79
  • NKTR $1.93
  • Technical
  • Relative Strength Index (RSI)
  • DMB 35.77
  • NKTR 44.49
  • Support Level
  • DMB $9.81
  • NKTR $0.43
  • Resistance Level
  • DMB $9.98
  • NKTR $0.68
  • Average True Range (ATR)
  • DMB 0.20
  • NKTR 0.08
  • MACD
  • DMB -0.03
  • NKTR 0.01
  • Stochastic Oscillator
  • DMB 26.50
  • NKTR 75.35

About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.

BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Share on Social Networks: